Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters

Chimeric Fusion Proteins Used for Therapy: Indications, Mechanisms, and Safety

(2015) Brian A. Baldo   DRUG SAFETY

Reductions in synaptic proteins and selective alteration of prepulse inhibition in male C57BL/6 mice after postnatal administration of a VIP receptor (VIPR2) agonist

(2015) Yukio Ago et al.   PSYCHOPHARMACOLOGY

Fc fusion as a platform technology: potential for modulating immunogenicity

(2015) Ditza Levin et al.   TRENDS IN BIOTECHNOLOGY

Co-opting biology to deliver drugs

(2014) Parisa Yousefpour et al.   BIOTECHNOLOGY AND BIOENGINEERING

A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice

(2014) A. Yee et al.   BLOOD

Novel AGLP-1 albumin fusion protein as a long-lasting agent for type 2 diabetes

(2014) Yong-Mo Kim et al.   BMB Reports

GSK2374697, a Novel Albumin-Binding Domain Antibody (AlbudAb), Extends Systemic Exposure of Exendin-4: First Study in Humans—PK/PD and Safety

(2014) R L O’Connor-Semmes et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Effects of Fusion Structure on the Expression and Bioactivity of Human Brain Natriuretic Peptide (BNP) Albumin Fusion Proteins

(2014) Yuedi Ding et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Changing paradigm of prophylaxis with longer acting factor concentrates

(2014) M. Carcao   HAEMOPHILIA

Enhancedin VivoEfficacy of a Type I Interferon Superagonist with Extended Plasma Half-life in a Mouse Model of Multiple Sclerosis

(2014) Daniel Harari et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Extending Serum Half-life of Albumin by Engineering Neonatal Fc Receptor (FcRn) Binding

(2014) Jan Terje Andersen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Differential intracellular signalling properties of the growth hormone receptor induced by the activation of an anti-GHR antibody

(2014) Hainan Lan et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Characterisation of a Novel Fc Conjugate of Macrophage Colony-stimulating Factor

(2014) Deborah J Gow et al.   MOLECULAR THERAPY

Comparative Study of Somatostatin-Human Serum Albumin Fusion Proteins and Natural Somatostatin on Receptor Binding, Internalization and Activation

(2014) Ying Peng et al.   PLoS One

Fusion of a Short Peptide that Binds Immunoglobulin G to a Recombinant Protein Substantially Increases Its Plasma Half-Life in Mice

(2014) Jonathan T. Sockolosky et al.   PLoS One

Half-life extension technologies for haemostatic agents

(2014) P. M. Mannucci   THROMBOSIS AND HAEMOSTASIS

Albumin as a versatile platform for drug half-life extension

(2013) Darrell Sleep et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity

(2013) Martin Lorenz et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Pharmacokinetics and Pharmacokinetic–Pharmacodynamic Correlations of Therapeutic Peptides

(2013) Lei Diao et al.   CLINICAL PHARMACOKINETICS

Neonatal Fc Receptor and its Role in the Absorption, Distribution, Metabolism and Excretion of Immunoglobulin G-Based Biotherapeutics

(2013) Craig Giragossian et al.   CURRENT DRUG METABOLISM

Proinsulin-Transferrin Fusion Protein as a Novel Long-Acting Insulin Analog for the Inhibition of Hepatic Glucose Production

(2013) Yan Wang et al.   DIABETES

A Long-Acting Human Growth Hormone With Delayed Clearance (VRS-317): Results of a Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Growth Hormone–Deficient Adults

(2013) Kevin C. J. Yuen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)

(2013) S. Zollner et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B

(2013) Jerry S. Powell et al.   NEW ENGLAND JOURNAL OF MEDICINE

A fusion protein derived from plants holds promising potential as a new oral therapy for type 2 diabetes

(2013) Jeehye Choi et al.   PLANT BIOTECHNOLOGY JOURNAL

PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins

(2013) M. Schlapschy et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin

(2013) Steven W. Pipe et al.   THROMBOSIS AND HAEMOSTASIS

Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII

(2013) Stefan Schulte   THROMBOSIS RESEARCH

Building better drugs: developing and regulating engineered therapeutic proteins

(2013) Chava Kimchi-Sarfaty et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Fusion protein linkers: Property, design and functionality

(2012) Xiaoying Chen et al.   ADVANCED DRUG DELIVERY REVIEWS

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients

(2012) J. S. Powell et al.   BLOOD

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients

(2012) E. Santagostino et al.   BLOOD

Conjugation of hyaluronan to proteins

(2012) Anna Mero et al.   CARBOHYDRATE POLYMERS

Fc-fusion proteins: new developments and future perspectives

(2012) Daniel M. Czajkowsky et al.   EMBO Molecular Medicine

A Novel Long-Acting Human Growth Hormone Fusion Protein (VRS-317): Enhanced In Vivo Potency and Half-Life

(2012) Jeffrey L. Cleland et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs

(2012) M. W. NOLTE et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Peptibodies: A flexible alternative format to antibodies

(2012) Grant Shimamoto et al.   mAbs

Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

(2012) C. F. McDonagh et al.   MOLECULAR CANCER THERAPEUTICS

GLP2-2G-XTEN: A Pharmaceutical Protein with Improved Serum Half-Life and Efficacy in a Rat Crohn’s Disease Model

(2012) Susan E. Alters et al.   PLoS One

Corifollitropin Alfa

(2011) Jamie D. Croxtall et al.   BIODRUGS

Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients

(2011) A. D. Shapiro et al.   BLOOD

Receptor-mediated activation of a proinsulin-transferrin fusion protein in hepatoma cells

(2011) Yan Wang et al.   JOURNAL OF CONTROLLED RELEASE

Biosimilar, biobetter and next generation therapeutic antibodies

(2011) Alain Beck   mAbs

Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies

(2011) Alain Beck et al.   mAbs

Human serum albumin: From bench to bedside

(2011) Gabriella Fanali et al.   MOLECULAR ASPECTS OF MEDICINE

Effects of Receptor Binding on Plasma Half-Life of Bifunctional Transferrin Fusion Proteins

(2011) Xiaoying Chen et al.   MOLECULAR PHARMACEUTICS

PEGylation of therapeutic proteins

(2010) Simona Jevševar et al.   Biotechnology Journal

Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein

(2010) Wolfgang Glaesner et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Designing a Long-Acting Human Growth Hormone (hGH) by Fusing the Carboxyl-Terminal Peptide of Human Chorionic Gonadotropin β-Subunit to the Coding Sequence of hGH

(2010) Fuad Fares et al.   ENDOCRINOLOGY

Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 2 or 3

(2010) David R. Nelson et al.   GASTROENTEROLOGY

Extending Half-life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding Domain

(2010) Jan Terje Andersen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR

(2010) Takuo Suzuki et al.   JOURNAL OF IMMUNOLOGY

Transferrin Fusion Technology: A Novel Approach to Prolonging Biological Half-Life of Insulinotropic Peptides

(2010) B.-J. Kim et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

ELPylated anti-human TNF therapeutic single-domain antibodies for prevention of lethal septic shock

(2010) Udo Conrad et al.   PLANT BIOTECHNOLOGY JOURNAL

Gcg-XTEN: An Improved Glucagon Capable of Preventing Hypoglycemia without Increasing Baseline Blood Glucose

(2010) Nathan C. Geething et al.   PLoS One

Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist

(2010) Qinghua Wang et al.   PLoS One

Strategies to Extend Plasma Half-Lives of Recombinant Antibodies

(2009) Roland E. Kontermann   BIODRUGS

Receptor-Fc fusion therapeutics, traps, and MIMETIBODY™ technology

(2009) Chichi Huang   CURRENT OPINION IN BIOTECHNOLOGY

Engineering a pharmacologically superior form of granulocyte-colony-stimulating factor by fusion with gelatin-like-protein polymer

(2009) Yan-Shan Huang et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Emerging PEGylated drugs

(2009) Jung Seok Kang et al.   EXPERT OPINION ON EMERGING DRUGS

Single Dose GLP-1-Tf Ameliorates Myocardial Ischemia/Reperfusion Injury

(2009) Muneaki Matsubara et al.   JOURNAL OF SURGICAL RESEARCH

A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner

(2009) Volker Schellenberger et al.   NATURE BIOTECHNOLOGY

Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn

(2009) Kristi Baker et al.   Seminars in Immunopathology

Half-life extension through albumin fusion technologies

(2009) Stefan Schulte   THROMBOSIS RESEARCH

Elastin-like polypeptides revolutionize recombinant protein expression and their biomedical application

(2009) Doreen M. Floss et al.   TRENDS IN BIOTECHNOLOGY

Mechanisms for cytotoxic effects of anti–tumor necrosis factor agents on transmembrane tumor necrosis factor α–expressing cells: Comparison among infliximab, etanercept, and adalimumab

(2008) Hiroki Mitoma et al.   ARTHRITIS AND RHEUMATISM

CNTO 530: Molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in mice

(2008) P.J. Bugelski et al.   JOURNAL OF BIOTECHNOLOGY

Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles

(2008) Felix Kratz   JOURNAL OF CONTROLLED RELEASE

Increasing the homogeneity, stability and activity of human serum albumin and interferon-α2b fusion protein by linker engineering

(2008) Hong Liang Zhao et al.   PROTEIN EXPRESSION AND PURIFICATION

PEGylation of somatropin (recombinant human growth hormone): Impact on its clearance in humans

(2008) R. Webster et al.   XENOBIOTICA